Abstracts Archive - Page 280 of 2425 - ACR Meeting Abstracts

Abstract Number: 1730 • ACR Convergence 2023
Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients
Rachel AUDO¹, Jérome Thireau², Louis Rauzier³, Marie Barozet¹, JACQUES MOREL⁴, Patrice Bideaux³, alain Lacampagne² and Claire Daien⁵, ¹CHU Montpellier, Montpellier, France, ²PhyMedExp INSERM U1046, Montpellier, France, ³PhyMedExp U1046, Montpellier, France, ⁴Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ⁵University Hospital, Montpellier, France
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high risk of cardiovascular (CV) risks, including accelerated atherosclerosis, left ventricular hypertrophy and decreased heart rate variability…
Abstract Number: 1625 • ACR Convergence 2023
Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning
santiago arciniegas¹, Matthias W. Wagner², Logi Vidarsson², Birgit Ertl-Wagner², Tala El Tal³, Asha Jeyanathan², Lawrence Ng², Linda Hiraki², Deborah Levy², George M. Ibrahim² and Andrea Knight², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Children's Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Childhood-onset SLE (cSLE) is characterised by a higher frequency of nervous system involvement, known…
Abstract Number: 1694 • ACR Convergence 2023
Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE
Prathyusha Bachali¹, Shimon Korish², Yanhua Hu³, Peter Schafer⁴, Amrie Grammer¹ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²Bristol Myers Squibb, Summit, NJ, ³Bristol Myers Squibb, Princeton, NJ, ⁴Bristol Myers Squibb, Belle Mead, NJ
Background/Purpose: Iberdomide is a high affinity cereblon ligand that promotes ubiquitylation and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3) transcription factors and, thereby altering…
Abstract Number: 1611 • ACR Convergence 2023
Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study
Linoy Israel¹, Victoria Furer², Atan Gross¹ and Jacob Ablin², ¹Weizmann Institute of Science, Rehovot, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Fibromyalgia (FM) is among the most common chronic pain conditions, clinically characterized by widespread pain and fatigue. FM pathogenesis remains unknown, leading to challenges…
Abstract Number: 1502 • ACR Convergence 2023
Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study
Kanako Kojima¹, Kunihiro Ichinose¹, Toshimasa Shimizu¹, Masataka Umeda¹, Takahisa Suzuki², Yoshikazu Nakashima³, Akitomo Okada⁴, Yoshiro Horai⁵, Keita Fujikawa⁶, Toshiyuki Aramaki⁷, Taiichiro Miyashita⁸, Masako Furuyama³, Naoki Matsuoka⁹ and Atsushi Kawakami¹⁰, ¹Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ³Nagasaki Kita Hospital, Nagasaki, Japan, ⁴National Hospital Organization Nagasaki Medical Center, Omura, Japan, ⁵Sasebo City General Hospital, Sasebo, Japan, ⁶Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, ⁷Sasebo Chuo Hospital, Sasebo, Japan, ⁸Miyashita Rheumatology Clinic, Omura, Japan, ⁹Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, ¹⁰Nagasaki University, Nagasaki, Japan
Background/Purpose: Belimumab (BEL), B cell-targeted biologic agent for systemic lupus erythematosus (SLE), is cumulating evidence such as reducing glucocorticoids and preventing the progressionof organ damage.…
Abstract Number: 0976 • ACR Convergence 2023
Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis
Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN
Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported…
Abstract Number: 0968 • ACR Convergence 2023
Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis
Yumeko Kawano¹, Dana Weisenfeld¹, Qing Liu¹, Mary Jeffway¹, Gregory McDermott¹, Kumar Dahal¹, Jennifer Stuart¹, Jacob Joseph², Tianrun Cai¹, Brittany Weber¹, Tianxi Cai³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Veteran's Affairs Boston Healthcare System, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular (CV) disease including heart failure (HF). HF is a heterogeneous condition that is…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 1726 • ACR Convergence 2023
Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis
Melissa Lim¹, Shaghayegh Foroozan², Zoya Qaiyum³, Michael Tang¹, Enoch Yau⁴ and Robert Inman¹, ¹University Health Network, Toronto, ON, Canada, ²University Health Network/University of Toronto, Toronto, ON, Canada, ³Krembil Research Institute, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory arthritis primarily affecting the axial skeleton and commonly coexists with gut and skin inflammation. Currently, patients with…
Abstract Number: 1622 • ACR Convergence 2023
Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality
Matthew Sherman¹, Payam Noroozi Farhad², Katherine Pak³, Iago Pinal-Fernandez³, Kakali Sarkar², Megan Neely⁴, Ira Targoff⁵, Frederick Miller⁶, Andrew Mammen⁷ and Lisa Rider⁸, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁵Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶NIH, NIEHS, Chapel Hill, NC, ⁷NIH, Bethesda, MD, ⁸NIEHS, NIH, Bethesda, MD
Background/Purpose: Myositis-associated autoantibodies (MAAs), such as anti-Ro52 autoantibodies (Abs), have been found to be associated with interstitial lung disease (ILD) and worse prognosis in the…
Abstract Number: 1728 • ACR Convergence 2023
A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis
Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada
Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
Abstract Number: 1696 • ACR Convergence 2023
Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis
Michael A. Smith¹, Dominic Sinibaldi², Saifur Rahman¹, Chia-Chien Chiang², Anna M. Hansen¹, Jill Henault¹, Carlos P. Roca³, Shu Wang¹, Kamelia Zerrouki¹, Rebecca Filippi¹, Christopher Groves¹, Zerai Manna⁴, Jun Chu⁴, Michael Davis⁴, sarthak gupta⁴, Christopher Morehouse¹, Melissa De los Reyes¹, Rachel Ettinger¹, Roland Kolbeck¹, Mariana Kaplan⁵, Miguel A. Sanjuan¹, Richard M. Siegel⁶, sarfaraz Hasni⁴ and Kerry A. Casey¹, ¹BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Data Science and AI, AstraZeneca, Gaithersburg, MD, ³Data Science and AI, AstraZeneca, Cambridge, United Kingdom, ⁴Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH); Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD, ⁶Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Much of our understanding of systemic lupus erythematosus (SLE) immunopathogenesis is derived from gene profiling studies, where core pathways such as neutrophil dysregulation and…
Abstract Number: 1631 • ACR Convergence 2023
Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis
Chloe Peyton¹, Tate Johnson¹, Joshua Baker², Yangyuna Yang¹, Punyasha Roul¹, Michael Duryee¹, Jill Poole¹, Geoffrey Thiele¹, Ted R Mikuls³ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) predisposes affected individuals to develop multiple chronic conditions (i.e., multimorbidity). Mechanisms underlying multimorbidity onset in RA are incompletely understood, particularly for…
Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Vasileios Kyttaris¹, Gelareh Atefi², Daniel Persons³, Christopher S. Ambrose⁴, Scott Milligan⁵ and Sandra Wu⁶, ¹BIDMC, Boston, MA, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³Trio Health, Denver, CO, ⁴AstraZeneca, Wilmington, DE, ⁵Trio Health, Analytics, Louisville, CO, ⁶AstraZeneca, Hockessin, DE
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.